Market research
UUD.F Pharmaxis Ltd
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.64
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- AU000000PXS5
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.64
About
About Pharmaxis Ltd
Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the UUD.F discussion.
5 years, 5 months ago
Pharmaxis Ltd is currently in a long term uptrend where the price is trading 19.9% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.3.
Pharmaxis Ltd's total revenue sank by 0.0% to $2M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 291.0% to $9M since the same quarter in the previous year.
Based on the above factors, Pharmaxis Ltd gets an overall score of 3/5.